HTRA1 and TGF-β1 concentrations in the aqueous humor of patients with neovascular age-related macular degeneration by Tosi, GIAN MARCO et al.
Biochemistry and Molecular Biology
HTRA1 and TGF-b1 Concentrations in the Aqueous Humor
of Patients With Neovascular Age-Related Macular
Degeneration
Gian Marco Tosi,1 Elena Caldi,2 Giovanni Neri,1 Elisabetta Nuti,1 Davide Marigliani,1 Stefano
Baiocchi,1 Claudio Traversi,1 Gabriele Cevenini,3 Antonio Tarantello,1 Fiorella Fusco,1 Federica
Nardi,2 Maurizio Orlandini,2 and Federico Galvagni2
1Ophthalmology Unit of the Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
2Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy
3Department of Medical Biotechnologies, University of Siena, Siena, Italy
Correspondence: Federico Galvagni,
Department of Biotechnology,
Chemistry and Pharmacy, University
of Siena, Via A. Moro, 2-53100-Siena,
Italy;
federico.galvagni@unisi.it.
Maurizio Orlandini, Department of
Biotechnology, Chemistry and Phar-
macy, University of Siena, Via A.
Moro, 2-53100-Siena, Italy;
maurizio.orlandini@unisi.it.
Submitted: October 14, 2016
Accepted: November 30, 2016
Citation: Tosi GM, Caldi E, Neri G, et
al. HTRA1 and TGF-b1 concentrations
in the aqueous humor of patients with
neovascular age-related macular de-
generation. Invest Ophthalmol Vis
Sci. 2017;58:162–167. DOI:10.1167/
iovs.16-20922
PURPOSE. The purpose of this study was to evaluate the expression of high-temperature
requirement A serine peptidase 1 (HTRA1), TGF-b1, bone morphogenetic protein 4 (BMP4),
growth differentiation factor 6 (GDF6), and VEGFA proteins in the aqueous humor of patients
with na¨ıve choroidal neovascularization (nCNV) secondary to AMD.
METHODS. We measured by ELISA the concentrations of HTRA1, TGF-b1, BMP4, GDF6, and
VEGFA in the aqueous humor of 23 patients affected by nCNV who received three
consecutive monthly intravitreal injections of 0.5 mg ranibizumab. Samples were collected at
baseline (before the first injection), month 1 (before the second injection), and month 2
(before the third injection). Twenty-three age-matched cataract patients served as controls.
RESULTS. Bone morphogenetic protein 4 and GDF6 were not detectable in any samples.
Baseline HTRA1 was higher than controls (P < 0.0001) and higher than both the month 1 (P
< 0.0001) and the month 2 (P < 0.0001) values. Baseline VEGFA was higher than controls (P
< 0.0001), not different from month 1 value (P ¼ 0.0821), but higher than month 2 value (P
< 0.0001). Baseline TGF-b1 was higher than controls (P ¼ 0.0015) and not different from
month 1 (P ¼ 0.129) and month 2 values (P ¼ 0.5529). No correlation was found in na¨ıve
patients between concentrations of HTRA1 and TGF-b1, HTRA 1 and VEGFA, or TGF-b1 and
VEGFA.
CONCLUSIONS. In nCNV patients, HTRA1 and TGF-b1 were significantly higher compared to
controls. After treatment, TGF-b1 was persistently elevated, while HTRA1 returned to control
levels, suggesting the involvement of TGF-b1 and HTRA1 in neovascular AMD and a VEGFA-
independent role for TGF-b1.
Keywords: HTRA1, TGF-b, VEGFA, age-related macular degeneration, choroidal
neovascularization
Age-related macular degeneration (AMD) is a major cause ofvisual loss in the elderly in developed countries. Neovas-
cular AMD (nAMD), a subtype of advanced AMD, is responsible
for almost 90% of severe visual loss due to AMD.1 Age-related
macular degeneration, including nAMD, is a multifactorial
disease whose pathogenesis has been linked to numerous
environmental and genetic factors.1 Through genome-wide
linkage and association, two major loci have been described as
being associated with an increased risk of AMD: the comple-
ment factor H (CFH) gene at 1q31 and the age-related
maculopathy susceptibility 2 (ARMS2)/high-temperature re-
quirement factor A1 (HTRA1) locus at 10q26.2–5 In particular,
single nucleotide polymorphisms (SNPs) of HTRA1 have been
associated with increased risk of nAMD in various ethnic
groups.4–7 Some studies have related specific HTRA1 alleles
with neovascular lesion size8 and with the response to
intravitreal anti-VEGF therapy in AMD patients,9 although this
association was not confirmed by others.10 Additionally,
overexpression of HTRA1 in the retinal pigment epithelium
of transgenic mice induces the exudative form of AMD.11,12
Nevertheless, the intraocular concentration of HTRA1 protein
in human patients affected by nAMD has, to our knowledge,
never been tested, and it remains to be elucidated whether the
SNPs of HTRA1 identified are causally linked to aberrant gene
expression or whether they are simply genetic markers.13 In
fact, the overexpression of HTRA1 protein and mRNA
associated with the HTRA1 risk allele rs11200638, initially
documented in human retinas from ex vivo studies,14–16 was
subsequently negated in multiple ex vivo and in vitro
studies.17–20
HTRA1 protein acts as a serine protease and is involved in
protein quality control and cell fate.21 The postulated pathways
through which HTRA1 might modulate AMD development
include the regulation of extracellular matrix (ECM) proteogly-
can degradation and the modulation of TGF-b family member
activity.5,14,21–25 Indeed, recent evidence has focused on the role
of TGF-b in favoring choroidal neovascularization (CNV), thus
advocating TGF-b blocking agents.26,27 However, despite the
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proposed role for HTRA1 in various neovascular diseas-
es,12,22,28–31 its mechanism of action on the TGF-b pathway is
still subject to debate. Both positive and negative effects of
HTRA1 on the processing or degradation of TGF-b1 and TGF-b
proteins have been proposed, with contrary effects on the
development of pathologic neovascularization.21–23,28,29 More-
over, Friedrich et al.23 recently showed that isoforms translated
from synonymous risk variants of the HTRA1 gene inefficiently
bind to and proteolyze TGF-b1, thus, against the current
tendency, suggesting a protective role for HTRA1 in nAMD. In
the present study, we evaluated the protein concentration of
HTRA1, TGF-b1, bone morphogenetic protein 4 (BMP4), growth
differentiation factor 6 (GDF6), and VEGFA in the aqueous
humor of patients affected by na¨ıve nAMD at baseline and after
intravitreal anti-VEGF injection in order to clarify the role of
these molecules in the development of CNV and AMD.
METHODS
Subjects
This prospective observational study comprised 23 patients
affected by active CNV secondary to AMD. All eyes were
examined and treated between June 2015 and February 2016
at the Ophthalmology Unit of the Department of Medicine,
Surgery and Neuroscience, Siena University Hospital, Siena,
Italy, after approval from the institutional review board. All
subjects were treated in accordance with the Declaration of
Helsinki. Patients were treated after being informed of the
nature, purpose, implications, and risks of the treatment and
after having signed a consent form.
The study enrolled patients who presented with CNV
secondary to AMD. The diagnosis was confirmed by fluores-
cein angiography (FA), indocyanine green angiography, and
spectral domain optical coherence tomography.
Patient demographics, study eye characteristics, and treat-
ment details were recorded, including best corrected visual
acuity (BCVA) measured using Early Treatment Diabetic
Retinopathy Study charts at a distance of 4 m at baseline and
during the course of follow-up; CNV angiographic subtype
(classic vs. occult); lesion size, determined by the greatest linear
dimension measured by FA examination before treatment;8
central macular thickness (CMT) at the baseline and each follow-
up visit; and number of injections required during follow-up.
All patients received three initial monthly injections
followed by a flexible pro re nata regimen. All patients were
followed for at least 8 months from their first injection.
None of the patients had received any previous treatment
for nAMD, nor had they undergone any previous ophthalmic
surgery, except cataract removal. Cataract surgery had to have
been performed at least 9 months prior to inclusion. Controls
were constituted by age-matched patients undergoing cataract
surgery. The exclusion criteria for controls were any ocular
disease except cataracts and any previous ophthalmic surgery.
Diabetes mellitus, use of immunosuppressive drugs, and
malignant tumors at any location were exclusion criteria for
both patients and controls.
Aqueous Humor Sample Collection
All patients with nAMD received three consecutive monthly
intravitreal injections of 0.5 mg ranibizumab. Aqueous samples
were collected at baseline (day of the first injection), month 1
(day of the second injection), and month 2 (day of the third
injection).
Anterior chamber taps were performed in the operating
room prior to each intravitreal injection (patients) and before
cataract surgery (controls) to obtain aqueous samples for
measurement of the expression of HTRA1, VEGFA, TGF-b1,
BMP4, and GDF6. A 30-gauge needle was inserted into the
anterior chamber and 0.15 to 0.2 mL of aqueous humor was
collected, centrifuged to remove cells and debris, aliquoted,
and frozen at 808C until analysis.
Assessment of the HTRA1, VEGFA, TGF-b1, BMP4,
and GDF6 Levels in the Patients’ Aqueous Humor
The HTRA1, VEGFA, TGF-b1, BMP4, and GDF6 concentrations
in the patients’ aqueous humor were measured by ELISA using
ELISA kits for human VEGFA, TGF-b1, and BMP4 (Quantikine
ELISA kit no. DVE00, no. DB100B, and no. DBP400,
respectively; R&D Systems, Minneapolis, MN, USA) and ELISA
kits for human HTRA1and GDF6 (no. MBS2504576 and no.
MBS2515203, respectively; MyBioSource, San Diego, CA, USA).
Each assay was performed according to the manufacturer’s
instructions. For each measurement of HTRA1, BMP4, and
GDF6 concentration, 25 lL of samples (50 lL for VEGFA) were
diluted to 100 lL using sample diluent buffer just prior to the
assay. To perform this multiplex analysis a single sample was
analyzed for each measurement due to sample volume
limitation. In fact, extraction of the quantity of aqueous humor
necessary to perform duplicate analyses for all of the five
molecules tested here would have caused a complete collapse
of the anterior chamber. To activate latent TGF-b1 to the
immunoreactive form, 25 lL of aqueous humor was treated
with 12.5 lL of 1N HCl and incubated for 10 minutes at room
temperature. The acidified samples were neutralized to pH 7.3
using 10.31 lL of 1.2N NaOH/0.5M HEPES and diluted to 100
lL using sample diluent buffer.
Statistical Analysis
The data analysis was performed using statistical software
(Prism 6; GraphPad, San Diego, CA, USA). The data are
presented as box and whisker plots displaying median, lower,
and upper quartiles and the minimum-maximum. The data
were evaluated using ANOVA. Differences in the protein
concentrations among the groups were estimated using
Student’s t-test and the nonparametric Mann-Whitney U test.
Two-tailed probabilities of less than 0.05 were considered
significant. The significance of correlations between protein
concentrations in the aqueous humor of na¨ıve AMD patients
and control samples was tested using Pearson’s correlation
coefficient.
RESULTS
The study compared the levels of HTRA1, VEGFA, TGF-b1,
BMP4, and GDF6 in the aqueous humor of 23 patients with
exudative AMD. Twenty-three age-matched cataract patients
constituted the control group. The mean age was 78.2 6 7.3
years in patients affected by nAMD and 73.6 6 4.8 in controls.
Age did not differ significantly between the two groups (P ¼
0.449). The male-to-female ratio was 1:2.875 and 1:3.28 in
patients and controls, respectively.
Concentrations of HTRA1, VEGFA, and TGF-b1 were
detected and measured by ELISA in the aqueous samples
analyzed, while the BMP4 and GDF6 concentrations detected
were similar to background values in all the samples analyzed
(data not shown).
Baseline HTRA1 concentration was higher in AMD patients
than in controls (baseline AMD median¼ 42.77 ng/mL [range
of variation¼ 19.86–135.09], controls median¼ 25.59 ng/mL
[11.53–53.80]; P < 0.0001) and higher than both the month 1
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(median ¼ 22.44 ng/mL [16.04–36.82]; P < 0.0001) and the
month 2 (median ¼ 24.77 ng/mL [16,67–44.75]; P < 0.0001)
values; HTRA1 month 1 and month 2 values were not
different from controls (month 1, P ¼ 0.5099; month 2, P ¼
0.9591). Baseline VEGFA was higher than in controls (baseline
AMD median¼ 11.42 pg/mL [1.46–20.70], controls median¼
7.59 [0–11.53]; P < 0.0001), not significantly different from
month 1 value (median¼ 7.15 pg/mL [0–19.19]; P¼ 0.0821),
but higher than month 2 value (median ¼ 1.17 pg/mL [0–
15.22]; P < 0.0001); VEGFA month 1 value was not
significantly different from controls (month 1, P ¼ 0.7486),
while the month 2 value was lower than controls (P ¼
0.0191). Baseline TGF-b1 was higher than controls (baseline
AMD median¼15.91 pg/mL [11.61–33.83], controls median¼
12.07 pg/mL [5.03–19.34]; P ¼ 0.0015) and not significantly
different from month 1 (median¼ 18.56 pg/mL [8.94–38.15];
P ¼ 0.129) or month 2 values (median ¼ 21.11 pg/mL [8.02–
38.85]; P¼0.5529); TGF-b1 month 1 and month 2 levels were
higher than control values (month 1, P < 0.0001; month 2, P
¼ 0.0012) (Fig. 1).
FIGURE 1. ELISA analysis of the aqueous levels of HTRA1, VEGFA, and TGF-b1. The (A) HTRA1, (B) VEGFA, and (C) TGF-b1 protein concentrations
in the aqueous humor of patients and controls were determined by ELISA. Data are presented as box and whisker plots displaying median, lower,
and upper quartiles (boxes) and minimum-maximum (whiskers). The P values beside each box were calculated by comparing na¨ıve or treated (once
or twice, Treat.1 and Treat.2, respectively) patient groups with a control group (Contr.). The P values calculated by comparing na¨ıve with treated
sample groups are indicated beside the brackets. The overall P value obtained by ANOVA is indicated above each graph.
HTRA1 and TGF-b1 Levels in AMD IOVS j January 2017 j Vol. 58 j No. 1 j 164
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/935965/ on 01/17/2017
In na¨ıve patients (at baseline) no correlation was found
between the aqueous humor concentrations of HTRA1 and
TGF-b1, HTRA1 and VEGFA, or TGF-b1 and VEGFA (Fig. 2).
Finally, considering the clinical characteristics of AMD
patients analyzed herein, we did not find any significant
correlation between HTRA1 concentration and any of the
following: baseline BCVA (P ¼ 0.623), BCVA change between
baseline and final follow-up visit (P¼0.391), angiographic CNV
type (P¼ 0.095), lesion size (P¼ 0.675), CMT at baseline (P¼
0.845), change in CMT between baseline and last follow-up
visit (P ¼ 0.535), or the number of injections (P ¼ 0.583).
DISCUSSION
This study analyzed the aqueous humor concentrations of
HTRA1, TGF-b1, and VEGFA at baseline and after one and two
intravitreal injections of ranibizumab in previously untreated
patients affected by nAMD. At baseline, not only VEGFA but
also HTRA1 and TGF-b1 concentrations were significantly
higher compared to controls. Intravitreal injections of ranibi-
zumab resulted in a significant reduction of VEGFA and HTRA1
concentrations, while TGF-b1 continued to be significantly
raised.
Our data give evidence of the role of HTRA1 protein in
nAMD, thus contributing potentially beneficial information
regarding nAMD pathogenesis. In fact, although genome-wide
association studies have linked HTRA1 SNP to nAMD, the
precise role of HTRA1 protein has remained elusive, since
numerous studies have recently confuted the previously
documented association between HTRA1 risk alleles and the
overexpression of HTRA1 protein and mRNA. Moreover, to our
knowledge, the intraocular expression of HTRA1 protein in
human patients affected by nAMD has never previously been
tested.14–20 HTRA1 acts as a serine protease, and as such, it
might contribute to angiogenesis by multiple mechanisms,
including the titration of growth factor activity and availability,
the regulation of ECM composition and integrity, and the
generation of angiogenically active ECM fragments.24,32 Our
data confirm the importance of proteases in ocular angiogen-
esis. In fact, the increased aqueous levels of HTRA1 detected
are in line with the previously described increased vitreous
concentration of metalloproteinases (MMPs) and aqueous
concentration of cathepsin in patients with nAMD.24 This
might be of primary importance, since inhibitors of MMPs are
negative regulators of na¨ıve CNV.24
With regard to the HTRA1 and VEGFA levels, while we
observed their similar trend in the sample groups, we did not
find any correlation between them in the na¨ıve untreated AMD
samples, suggesting that HTRA1 and VEGFA did not directly
regulate each other: This is consistent with the in vitro findings
of Ng et al.19
One of the most documented functions of HTRA1 involves
its association with the TGF-b family.21–23,33,34 HTRA1 is
thought to down-regulate TGF-b signaling both in AMD and
in cerebral small vessel disease.21–23,33 However, the inhibitory
effect of HTRA1 on TGF-b has recently been confuted in
cerebral small vessel disease.34 TGF-b family members have a
pleiotropic effect and may have different roles in the regulation
of vascular endothelial and smooth muscle cells, being pro- or
antiangiogenic in a context-dependent way.35 However, recent
and mounting evidence suggests a prominent role for TGF-b in
favoring nAMD, thus advocating a TGF-b–blocking agent in
nAMD treatment.26 In the present series, we showed increased
aqueous expression of TGF-b1 at baseline, confirming the data
of Bai et al.26 who documented increased vitreous TGF-b level
in patients with nAMD. Interestingly, TGF-b1 expression was
not correlated with the expression of either VEGFA or HTRA1
in na¨ıve untreated AMD patients, and notwithstanding
treatment, TGF-b1 levels remained significantly higher than
in controls. This suggests that the levels of these proteins are
not directly linked to one another and that each of them might
contribute to nAMD genesis and development, but in an
independent way, as previously suggested by the analysis of the
mouse model overexpressing HTRA1.30
The increased concentration of TGF-b1 at baseline and the
lack of a decrease in TGF-b1 following anti-VEGF intravitreal
injections could lead us to hypothesize a potential beneficial
effect on the disease course of nAMD of direct antagonism by
TGF-b1. However, the present findings should be studied in
greater depth through concomitant analysis of TGF-b2, which
has been shown to be expressed in the aqueous humor under
physiological conditions36 and through quantification of the
activated TGF-b among the total TGF-b protein concentrations.
The present study demonstrates a potential causative role of
HTRA1 protein in nAMD and confirms the possibility of
FIGURE 2. Correlation analysis of aqueous humor concentrations of
HTRA1, VEGFA, and TGF-b1. Data are presented as scatter plots. In
na¨ıve AMD patients, no correlation was found between concentrations
of (A) HTRA1 and TGF-b1, (B) HTRA1 and VEGFA, or (C) TGF-b1 and
VEGFA. The correlation coefficient (r) was obtained using linear
regression (Pearson’s) analysis.
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blocking TGF-b1 as an additional treatment for nAMD.
However, further studies using a larger number of samples
are needed in order to verify this issue and to better
understand the connection between HTRA1 and the TGF-b
family members, as well as their precise role in nAMD.
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